Mark Leonard Singleton - 21 Mar 2023 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
SVP & CFO
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
21 Mar 2023
Net transactions value
$0
Form type
4
Filing time
23 Mar 2023, 16:15:33 UTC
Previous filing
05 Apr 2022
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise +18,625 18,625 21 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -18,625 -25% $0.000000 55,875 21 Mar 2023 Class A Common Stock 18,625 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The original grant of 74,500 RSUs vests in four approximately equal annual installments that began on March 21, 2023.